PixantroneCAS# 144510-96-3 |
- Lidocaine
Catalog No.:BCC1084
CAS No.:137-58-6
- Mianserin HCl
Catalog No.:BCC1114
CAS No.:21535-47-7
- Loratadine
Catalog No.:BCC1262
CAS No.:79794-75-5
- Bavisant
Catalog No.:BCC1402
CAS No.:929622-08-2
- Bavisant dihydrochloride
Catalog No.:BCC1403
CAS No.:929622-09-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 144510-96-3 | SDF | Download SDF |
PubChem ID | 134019 | Appearance | Powder |
Formula | C17H19N5O2 | M.Wt | 325.37 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | BBR 2778 | ||
Solubility | Soluble in DMSO | ||
Chemical Name | 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione | ||
SMILES | C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN | ||
Standard InChIKey | PEZPMAYDXJQYRV-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Pixantrone Dilution Calculator
Pixantrone Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.0734 mL | 15.3671 mL | 30.7342 mL | 61.4685 mL | 76.8356 mL |
5 mM | 0.6147 mL | 3.0734 mL | 6.1468 mL | 12.2937 mL | 15.3671 mL |
10 mM | 0.3073 mL | 1.5367 mL | 3.0734 mL | 6.1468 mL | 7.6836 mL |
50 mM | 0.0615 mL | 0.3073 mL | 0.6147 mL | 1.2294 mL | 1.5367 mL |
100 mM | 0.0307 mL | 0.1537 mL | 0.3073 mL | 0.6147 mL | 0.7684 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pixantrone is a topoisomerase II inhibitor and DNA intercalator, with anti-tumor activity.
In Vitro:Pixantrone is a topoisomerase II inhibitor. Pixantrone induces cell death in multiple cancer cell lines independent of cell cycle perturbation, with IC50s of 37.3 nM, 126 nM and 136 nM for T47D, MCF-10A and OVCAR5 cells, respectively. Pixantrone induces DNA damage at high concentrations (500 nM) but not at concentrations (100 nM) sufficient to kill PANC1 cells. Pixantrone (25 or 100 nM) induces severe chromosomal aberrations and mitotic catastrophe in PANC1 cells. Pixantrone (100 nM) may disrupt chromosome segregation because of generating merotelic kinetochore attachments that cause chromosome non-disjunction[1]. Pixantrone potently inhibits growth of human Leukemia K562 cells, etoposide-resistant K/VP.5 cells, MDCK and ABCB1-transfected MDCK/MDR cells, with IC50s of 0.10 μM, 0.56 μM, 0.058 μM and 4.5 μM, respectively. Pixantrone (0.01-0.2 μM) leads to a concentration-dependent formation of linear DNA through acting on topoisomerase IIα. Pixantrone produces semiquinone free radicals in an enzymatic reducing system, although not in a cellular system, most likely due to low cellular uptake[2]. Pixantrone (0.01-10 μM) shows potent inhibitory activities against rat 97-116 peptide-specific T cell proliferation[4].
In Vivo:Pixantrone (27 mg/kg) does not worsen pre-existing moderate degenerative cardiomyopathy in doxorubicin-pretreated mice, by i.v. one dose every 7 days repeated thrice (q7d × 3). Pixantrone (27 mg/kg) causes minimal cardiotoxic in mice following repeated treatment cycles. Moreover, Pixantrone results in less mortality than mitoxantrone in doxorubicin-pretreated mice[3]. Pixantrone (16.25 mg/kg i.v, q7d × 3) modulates Lymph node cells (LNC) responses, and affacts T cell subpopulations in TAChR-immunized Lewis rats. Pixantrone also shows preventive and therapeutic effect in experimental autoimmune myasthenia gravis (EAMG) rats[4].
References:
[1]. Beeharry N, et al. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. Cancer Biol Ther. 2015;16(9):1397-406.
[2]. Hasinoff BB, et al. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform. J Pharmacol Exp Ther. 2016 Feb;356(2):397-409.
[3]. Cavalletti E, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs. 2007 Jun;25(3):187-95.
[4]. Ubiali F, et al. Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. J Immunol. 2008 Feb 15;180(4):2696-703.
- Cannabisin D
Catalog No.:BCN2547
CAS No.:144506-19-4
- Rotundatin
Catalog No.:BCN7856
CAS No.:144506-16-1
- Licochalcone C
Catalog No.:BCN6334
CAS No.:144506-14-9
- Tirofiban
Catalog No.:BCC4868
CAS No.:144494-65-5
- Clopidogrel Related Compound A
Catalog No.:BCN2687
CAS No.:144457-28-3
- Beta-Aflatrem
Catalog No.:BCN6699
CAS No.:144446-23-1
- Goniodiol 8-acetate
Catalog No.:BCN4787
CAS No.:144429-71-0
- Aflavarin
Catalog No.:BCN7410
CAS No.:144429-67-4
- 3-O-(E)-p-Coumaroylbetulin
Catalog No.:BCN6247
CAS No.:144424-80-6
- Canophyllal
Catalog No.:BCN7441
CAS No.:14440-40-5
- 3-Oxopomolic acid methyl ester
Catalog No.:BCN3723
CAS No.:14440-23-4
- 8-(7-Hydroxy-3,7-dimethyl-2,5-octadienyloxy)psoralen
Catalog No.:BCN1567
CAS No.:144398-34-5
- Isorhynchophyllic acid
Catalog No.:BCN4980
CAS No.:144525-05-3
- Oxyresveratrol 3'-O-beta-D-glucopyranoside
Catalog No.:BCN1566
CAS No.:144525-40-6
- Murrayanol
Catalog No.:BCN3178
CAS No.:144525-81-5
- ME0328
Catalog No.:BCC3995
CAS No.:1445251-22-8
- GSK 2837808A
Catalog No.:BCC5607
CAS No.:1445879-21-9
- Kanshone H
Catalog No.:BCN7627
CAS No.:1445952-33-9
- Paliperidone
Catalog No.:BCC3834
CAS No.:144598-75-4
- IRL-1038
Catalog No.:BCC5730
CAS No.:144602-02-8
- Schisanlignone C
Catalog No.:BCN3629
CAS No.:144606-83-7
- Schisanlignone D
Catalog No.:BCN3630
CAS No.:144606-84-8
- Isomahanine
Catalog No.:BCN3177
CAS No.:144606-95-1
- CPI-203
Catalog No.:BCC4099
CAS No.:1446144-04-2
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma.[Pubmed:28334700]
Chemotherapy. 2017;62(3):187-191.
Aggressive non-Hodgkin lymphoma is associated with poor long-term survival after relapse or resistance to chemotherapy. We report a case of aggressive non-Hodgkin lymphoma refractory to first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and second-line R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) chemotherapy treatments. The patient achieved remission with single-agent Pixantrone, and received a consolidation with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) chemotherapy and autologous stem cell transplantation. He received consolidation radiotherapy on the site of bulky disease. At 20 months from transplant, the disease is in continuous complete remission. The successful use of Pixantrone as a bridge to transplant is highlighted, together with the absence of serious side effects.
Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.[Pubmed:27757832]
Drugs. 2016 Oct;76(16):1579-1586.
Pixantrone (Pixuvri((R))) is an aza-anthracenedione with a novel mode of action that is conditionally approved in the EU for use as monotherapy in adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (NHL). In the randomized, open-label, multinational, phase 3 PIX301 trial in patients with multiply relapsed or refractory aggressive NHL, the complete response (CR) plus unconfirmed CR (uCR) rate at the end of treatment (primary endpoint) was significantly higher with intravenous Pixantrone monotherapy than with a single-agent comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone or gemcitabine). Post hoc analysis also demonstrated a significantly higher CR/uCR rate in the subgroup of patients with centrally confirmed aggressive B-cell NHL who were receiving Pixantrone versus a comparator agent as third- or fourth-line therapy. Pixantrone was generally well tolerated in PIX301, with a manageable adverse event profile. In conclusion, Pixantrone is a useful option in patients with multiply relapsed or refractory aggressive B-cell NHL. Further results examining the use of Pixantrone in combination with rituximab in patients previously treated with rituximab-containing regimens are awaited with interest.